TATatsuya Aonuma

Tatsuya Aonuma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatsuya Aonuma has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study

    by Hirofumi Sakuma, Satoshi Kawaguchi, Yuya Kitani, Tatsuya Aonuma, Naoko Kawabata, Erika Saito, Akiho Minoshima, Shingo Kunioka, Hiroyuki Kamiya, Naoki Nakagawa

    Background/Objectives: Transcatheter aortic valve replacement (TAVR) may improve systemic hemodynamics and kidney perfusion; however, its effect on long-term kidney function remains unclear. We evaluated kidney function trajectories before and after TAVR in patients with and without chronic kidney disease (CKD). Methods: This single-center retrospective cohort study included patients with severe aortic stenosis (AS) who underwent TAVR between June 2016 and December 2024. Overall, 314 eligible patients were classified by baseline estimated glomerular filtration rate (eGFR) as without CKD (≥60 mL/min/1.73 m2) or with CKD (2). Linear mixed-effects models estimated pre- and post-TAVR eGFR slopes, which were compared between groups after covariate adjustment. Results: Median follow-up was 2.0 years. Adjusted pre-TAVR eGFR slopes were −2.11 (95% confidence interval [CI], −3.34 to −0.89) mL/min/1.73 m2/year in patients without CKD and −2.83 (95% CI, −3.65 to −2.01) mL/min/1.73 m2/year in patients with CKD. The post-TAVR slopes were −4.02 (95% CI, −5.68 to −2.35) mL/min/1.73 m2/year in patients without CKD and −0.83 (95% CI, −2.04 to 0.39) mL/min/1.73 m2/year in patients with CKD, with a significant group difference of 3.19 (95% CI, 1.44 to 4.94) mL/min/1.73 m2/year (p < 0.001). In patients with CKD, the post-TAVR slope improved relative to the pre-TAVR slope by 2.01 (95% CI, 0.51 to 3.50) mL/min/1.73 m2/year (p < 0.01), whereas no significant change was observed in those without CKD. Conclusions: eGFR decline after TAVR was attenuated in patients with CKD compared with those without CKD, suggesting that kidney function may be preserved through hemodynamic improvement following TAVR.

  • Open Access

    A case of rapid rupture of a calcified amorphous tumor observed by echocardiography

    by Kentaro Shirakura, Ryohei Ushioda, Masahiro Tsutsui, Shingo Kunioka, Nobuhiro Mochizuki, Tatsuya Aonuma, Naoko Kawabata, Erika Saitoh, Naoki Nakagawa, Hiroyuki Kamiya

    A calcified amorphous tumor (CAT) of the heart is a rare, non-neoplastic, intracavitary cardiac mass. Histological examination reveals the presence of calcified and amorphous fibrous material with underlying chronic inflammation. Some studies have reported that CAT typically exhibits rapid growth. However, we observed a case in which CAT unexpectedly ruptured within approximately two weeks. There was no cerebral infarction or significant valvular disease, therefore we were not sure about the indication for surgery; however considering the epidemiological possibility of CAT, we decided to operate and were able to treat the patient without complications.


  • Open Access

    MicroRNA-150 Deletion from Adult Myofibroblasts Augments Maladaptive Cardiac Remodeling Following Chronic Myocardial Infarction

    by Satoshi Kawaguchi, Marisa N. Sepúlveda, Jian-Peng Teoh, Taiki Hayasaka, Bruno Moukette, Tatsuya Aonuma, Hyun Cheol Roh, Meena S. Madhur, Il-Man Kim

    MicroRNA (miR: small noncoding RNA)-150 is evolutionarily conserved and is downregulated in patients with diverse forms of heart failure (HF) and in multiple mouse models of HF. Moreover, miR-150 is markedly correlated with the outcome of patients with HF. We previously reported that systemic or cardiomyocyte-derived miR-150 in mice elicited myocardial protection through the inhibition of cardiomyocyte death, without affecting neovascularization and T cell infiltration. Our mechanistic studies also showed that the protective roles of miR-150 in ischemic mouse hearts and human cardiac fibroblasts were, in part, attributed to the inhibition of fibroblast activation via the repression of multiple profibrotic genes. However, the extent to which miR-150 expression in adult myofibroblasts (MFs) modulates the response to myocardial infarction (MI) remains unknown. Here, we develop a novel 4-hydroxytamoxifen-inducible MF-specific miR-150 conditional knockout mouse model and demonstrate that the mouse line exhibits worse cardiac dysfunction after MI. Our studies further reveal that miR-150 ablation selectively in adult MFs exacerbates cardiac damage and apoptosis after chronic MI. Lastly, MF-specific miR-150 deletion in adult mice promotes the expression of proinflammatory and profibrotic genes as well as cardiac fibrosis following chronic MI. Our findings indicate a key protective role for MF-derived miR-150 in modulating post-MI responses.


  • Severe mitral regurgitation in non-hypertrophic cardiomyopathy caused by systolic anterior motion of the mitral valve

    by Tatsuya Aonuma, Naoko Kawabata, Ayumi Date, Erika Saito, Kazumi Akasaka, Hiroyuki Kamiya, Naoki Nakagawa

  • MiR-150 Attenuates Maladaptive Cardiac Remodeling Mediated by Long Noncoding RNA MIAT and Directly Represses Profibrotic Hoxa4

    by Tatsuya Aonuma, Bruno Moukette, Satoshi Kawaguchi, Nipuni P. Barupala, Marisa N. Sepúlveda, Kyle Frick, Yaoliang Tang, Maya Guglin, Subha V. Raman, Chenleng Cai, et al.

    Background: MicroRNA-150 (miR-150) plays a protective role in heart failure (HF). Long noncoding RNA, myocardial infarction–associated transcript (MIAT) regulates miR-150 function in vitro by direct interaction. Concurrent with miR-150 downregulation, MIAT is upregulated in failing hearts, and gain-of-function single-nucleotide polymorphisms in MIAT are associated with increased risk of myocardial infarction (MI) in humans. Despite the correlative relationship between MIAT and miR-150 in HF, their in vivo functional relationship has never been established, and molecular mechanisms by which these 2 noncoding RNAs regulate cardiac protection remain elusive. Methods: We use MIAT KO (knockout), Hoxa4 (homeobox a4) KO, MIAT TG (transgenic), and miR-150 TG mice. We also develop DTG (double TG) mice overexpressing MIAT and miR-150. We then use a mouse model of MI followed by cardiac functional, structural, and mechanistic studies by echocardiography, immunohistochemistry, transcriptome profiling, Western blotting, and quantitative real-time reverse transcription-polymerase chain reaction. Moreover, we perform expression analyses in hearts from patients with HF. Lastly, we investigate cardiac fibroblast activation using primary adult human cardiac fibroblasts and in vitro assays to define the conserved MIAT/miR-150/HOXA4 axis. Results: Using novel mouse models, we demonstrate that genetic overexpression of MIAT worsens cardiac remodeling, while genetic deletion of MIAT protects hearts against MI. Importantly, miR-150 overexpression attenuates the detrimental post-MI effects caused by MIAT. Genome-wide transcriptomic analysis of MIAT null mouse hearts identifies Hoxa4 as a novel downstream target of the MIAT/miR-150 axis. Hoxa4 is upregulated in cardiac fibroblasts isolated from ischemic myocardium and subjected to hypoxia/reoxygenation. HOXA4 is also upregulated in patients with HF. Moreover, Hoxa4 deficiency in mice protects the heart from MI. Lastly, protective actions of cardiac fibroblast miR-150 are partially attributed to the direct and functional repression of profibrotic Hoxa4 . Conclusions: Our findings delineate a pivotal functional interaction among MIAT, miR-150, and Hoxa4 as a novel regulatory mechanism pertinent to ischemic HF.


  • Open Access

    Adult Accessory Mitral Valve with Septal Hypertrophy

    by Tatsuya Aonuma, Naofumi Takehara, Erika Saito, Naoyuki Hasebe